ArticleEBioMedicine2015
Arterial Blood, Rather Than Venous Blood, is a Better Source for Circulating Melanoma Cells.
Article in EBioMedicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 45 citations in OpenAlex.
- A Prospective Phase II Trial of Radioembolization for Treatment of Uveal Melanoma Hepatic Metastasis.Radiology · 2019Trial
- Yttrium-90 Radioembolization as a Safe and Effective Treatment Option for Hepatic Uveal Melanoma Metastases.Cardiovascular and interventional radiology · 2026Article
- The Dynamic Landscape of the Coagulome of Metastatic Malignant Melanoma.International journal of molecular sciences · 2025Article
- [Circulating tumor cells in uveal melanoma : "The needle in the haystack"].Die Ophthalmologie · 2024Review
- Heterogeneity and molecular landscape of melanoma: implications for targeted therapy.Molecular biomedicine · 2024Review
- Peripheral arterial rather than venous blood is a better source of circulating tumor cells in early lung cancer.Thoracic cancer · 2024Article
- Biopsy Techniques for Musculoskeletal Tumors: Basic Principles and Specialized Techniques.Current oncology (Toronto, Ont.) · 2024Review
- Circulating tumor cell-derived preclinical models: current status and future perspectives.Cell death & disease · 2023Review
- Assessment of Different Circulating Tumor Cell Platforms for Uveal Melanoma: Potential Impact for Future Routine Clinical Practice.International journal of molecular sciences · 2023Article
- Technologies for Viable Circulating Tumor Cell Isolation.International journal of molecular sciences · 2022Review
- Article
- Circulating Neoplastic-Immune Hybrid Cells Predict Metastatic Progression in Uveal Melanoma.Cancers · 2022Article
- Future perspectives of uveal melanoma blood based biomarkers.British journal of cancer · 2022Review
- Liquid biopsies in primary and secondary bone cancers.Cancer drug resistance (Alhambra, Calif.) · 2022Review
- Review
- Article
- Development of an arteriolar niche and self-renewal of breast cancer stem cells by lysophosphatidic acid/protein kinase D signaling.Communications biology · 2021Article
- Circulating Tumor Cells from Enumeration to Analysis: Current Challenges and Future Opportunities.Cancers · 2021Review
- Liquid Biopsy in Uveal Melanoma: Are We There Yet?Ocular oncology and pathology · 2021Review
- Monosomy 3 Influences Epithelial-Mesenchymal Transition Gene Expression in Uveal Melanoma Patients; Consequences for Liquid Biopsy.International journal of molecular sciences · 2020Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundCTCs provide prognostic information and their application is under investigation in multiple tumor types. Of the multiple variables inherent in any such process, none is more important to outcome than the appropriateness of the sample source. To address this question, we investigated CTCs in paired peripheral venous and arterial blood specimens obtained from stage IV uveal melanoma patients.
methodsBlood specimens were obtained from both common femoral arteries and antecubital veins in 17 uveal melanoma patients with multiple hepatic metastases for CTC measurements. FINDING: CTCs were detectable with greater frequency (100%) and in larger numbers (median 5, range 1 to 168) in all arterial blood specimens than in venous samples (52.9%; median 1, range 0 to 8). Patients with hepatic as well as extra-hepatic metastasis showed higher number of arterial CTCs, compared to patients with liver-only metastasis (p = 0.003). There was no significant association between the number of arterial CTCs and the tumor burden within the liver in patients who had liver-only metastases.
interpretationOur data indicate that arterial blood specimens might be a better source of circulating uveal melanoma cells. Although less conveniently processed, perhaps arterial blood should be evaluated as sample source for measurement of CTCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.